Abstract
Opioids are commonly used for acute migraine treatment despite evidence suggesting that they may increase the risk of migraine chronification. Limited evidence also suggests that prior use of opioids by migraine patients may reduce responsiveness to subsequent acute migraine therapies including triptans. Telcagepant is a novel investigational oral CGRP receptor antagonist with acute antimigraine efficacy comparable to oral triptans. We performed a post-hoc analysis of data from a randomized double-blind placebo-controlled trial to explore whether the efficacy of telcagepant appeared to be influenced by patient's prior use of, and response to, opioids.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
